专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010062676A1 MODELING EVOLUTIONARY DYNAMICS OF HEPATITIS-C RESISTANT VARIANTS IN PATIENTS DOSED WITH TELAPREVIR 审中-公开
标题翻译：建立患有TELAPREVIR的患者中耐药性变异体的演变动力学
公开(公告)号：WO2010062676A1
公开(公告)日：2010-06-03
申请号：PCT/US2009/062738
申请日：2009-10-30
申请人： VERTEX PHARMACEUTICALS INCORPORATED , ADIWIJAYA, Bambang Senoaji , GARG, Varun
发明人： ADIWIJAYA, Bambang Senoaji , GARG, Varun
IPC分类号： G06F19/00
CPC分类号： G16H50/20 , G06F19/00
摘要： The invention relates to a method of measuring and predicting the evolutionary dynamics of HCV genotype 1 population when dosed with a composition including a protease inhibitor. The method includes using a multivariant viral kinetic model consisting of two-step process of random mutation and selection by competition among various HCV variants for shared limited healthy target cells constituting replication space to measure and predict the evolutionary dynamics of HCV genotype (1) population thereby providing useful information on dosing and responsiveness to compositions including a protease inhibitor. The model parameters are estimated from pre-, during-, and post-dosing plasma HCV RNA and post-dosing clonal sequencing data using a scheme that integrates all dosing periods to impose consistency and to improve estimation results.
摘要翻译：本发明涉及当给予包含蛋白酶抑制剂的组合物时测量和预测HCV基因型1群体的进化动力学的方法。该方法包括使用多变量病毒动力学模型，其由随机突变的两步过程和各种HCV变体之间的竞争选择构成复制空间的共享有限健康靶细胞，从而测量和预测HCV基因型（1）群体的进化动力学提供关于给药和对包括蛋白酶抑制剂的组合物的反应性的有用信息。模型参数是从给药前，给药前和给药后血浆HCV RNA和给药后克隆测序数据估计的，该方案使用整合所有给药期以施加一致性并改善估计结果的方案。

2. 发明申请

WO2011156545A1 VIRAL DYNAMIC MODEL FOR HCV COMBINATION THERAPY 审中-公开
标题翻译： HCV组合治疗的病毒动态模型
公开(公告)号：WO2011156545A1
公开(公告)日：2011-12-15
申请号：PCT/US2011/039712
申请日：2011-06-09
申请人： VERTEX PHARMACEUTICALS INCORPORATED , ADIWIJAYA, Bambang, Senoaji , CARON, Paul, R. , GARG, Varun , KIEFFER, Tara, Lynn , KWONG, Ann Dak-Yee , KAUFFMAN, Robert, S.
发明人： ADIWIJAYA, Bambang, Senoaji , CARON, Paul, R. , GARG, Varun , KIEFFER, Tara, Lynn , KWONG, Ann Dak-Yee , KAUFFMAN, Robert, S.
IPC分类号： G01N33/576 , G06F19/00
CPC分类号： G01N33/5767
摘要： A model of HCV dynamics to quantify responses in subjects dosed with a combination of PR and a protease inhibitor is provided. The model quantitatively predicts clinical outcomes of alternative durations of the protease inhibitor and PR, and these predictions correspond well to the empirically observed outcomes in clinical trials. This model accounts for multiple HCV variants with reduced replicative fitness and susceptibility to protease inhibitors, and examines how these properties of the variants contribute to the HCV dynamics in subjects dosed with the triple combination therapy. Furthermore, the model provides insight into the mechanisms of how protease inhibitor-based regimens increase the SVR rate and reduce total duration of treatment, and predicts that the protease inhibitor-mediated reduction in the overall fitness of the HCV quasispecies, along with potential synergy of protease inhibitors and PR, may enable previous PR nonresponders to achieve SVR on T/PR treatment.
摘要翻译：提供了HCV动力学模型，用于定量给予PR和蛋白酶抑制剂组合的受试者的反应。该模型定量预测了蛋白酶抑制剂和PR的替代持续时间的临床结果，这些预测与临床试验中经验观察到的结果很好地吻合。该模型考虑了多种HCV变异体，其具有降低的复制适应性和对蛋白酶抑制剂的易感性，并且检查这些变体的这些性质如何有助于用三联组合治疗的受试者的HCV动态。此外，该模型提供了对蛋白酶抑制剂方案如何增加SVR率和减少治疗总持续时间的机制的了解，并预测蛋白酶抑制剂介导的HCV准种总体适应性的降低以及潜在的协同作用蛋白酶抑制剂和PR，可以使先前的PR无应答者在T / PR治疗上实现SVR。

3. 发明申请

WO2012109646A1 TREATMENT OF HCV IN HIV INFECTION PATIENTS 审中-公开
标题翻译：艾滋病毒感染患者HCV治疗
公开(公告)号：WO2012109646A1
公开(公告)日：2012-08-16
申请号：PCT/US2012/024850
申请日：2012-02-13
申请人： GARG, Varun , VERTEX PHARMACEUTICALS INCORPORATED
发明人： GARG, Varun
IPC分类号： A61K31/497 , A61K31/7056 , A61K38/21 , A61K31/12 , A61K31/18
CPC分类号： A61K31/497 , A61K31/7056 , A61K38/212 , A61K2300/00
摘要： The disclosure relates to method of treatment, dosage regimens, and medicaments comprising telaprevir for the treatment of hepatitis C virus in a patient infected with HIV. Also disclosed are methods of treatment, dosage regimens, and medicaments comprising telaprevir in combination with one or more of an interferon, ribavirin or anti-HIV agent.
摘要翻译：本公开涉及治疗方法，剂量方案和药物，其包括特拉匹韦用于在感染HIV的患者中治疗丙型肝炎病毒。还公开了治疗方法，剂量方案和药物，其包括与一种或多种干扰素，利巴韦林或抗HIV剂组合的特拉匹韦。

4. 发明申请

WO2010053942A1 METHODS FOR TREATING HEPATITIS C VIRUS INFECTION 审中-公开
标题翻译：治疗乙型肝炎病毒感染的方法
公开(公告)号：WO2010053942A1
公开(公告)日：2010-05-14
申请号：PCT/US2009/063208
申请日：2009-11-04
申请人： VERTEX PHARMACEUTICALS INCORPORATED , HENSHAW, Joshua , GARG, Varun , AHMAD, Alaa, M. , DUBEY, Neeraj
发明人： HENSHAW, Joshua , GARG, Varun , AHMAD, Alaa, M. , DUBEY, Neeraj
IPC分类号： A61P31/12 , A61K38/21 , A61K31/7056
CPC分类号： A61K31/7056 , A61K38/212 , A61K2300/00
摘要： A method of treating a patient infected with HCV comprises administering to the patient VX-950 and interferon. In the method, an interferon trough level and/or a VX-950 trough level of the patient independently are monitored. The method further includes determining whether or not to adjust: subsequent administration of VX-950 to obtain a minimum target VX-950 trough level of about 1,500 ng/mL; subsequent administration of interferon to obtain a minimum target interferon trough level of about 5,000 pg/mL; or subsequent administration of VX-950 and interferon to obtain said minimum target trough levels.
摘要翻译：治疗感染HCV的患者的方法包括向患者施用VX-950和干扰素。在该方法中，独立地监测患者的干扰素谷值和/或VX-950谷值。该方法还包括确定是否调整：随后施用VX-950以获得约1,500ng / mL的最小目标VX-950槽水平; 随后施用干扰素以获得约5,000pg / mL的最小目标干扰素谷水平; 或随后施用VX-950和干扰素以获得所述最小目标谷水平。

5. 发明申请

WO2014004381A3 NON-DISRUPTIVE CONTROLLER REPLACEMENT IN NETWORK STORAGE SYSTEMS 审中-公开
公开(公告)号：WO2014004381A3
公开(公告)日：2014-01-03
申请号：PCT/US2013/047335
申请日：2013-06-24
申请人： NETAPP, INC. , ELPULA, Sravana Kumar , GARG, Varun , VENI, Sakshi Chaitanya
发明人： ELPULA, Sravana Kumar , GARG, Varun , VENI, Sakshi Chaitanya
IPC分类号： G06F11/20
摘要： A network-based storage system includes multiple system controllers and multiple physical storage devices arranged into aggregates, with each storage device having an ownership portion indicating a system controller to which it belongs. First and second system controllers are in communication with each other, the storage devices, and a separate host server, and each system controller can be designated as a system node that controls a respective aggregate of storage devices and reads and writes to the storage devices based upon commands from the separate host server. The first system controller controls a first system node and can facilitate an automated hotswap replacement of the second system controller that originally controls a second system node with a separate third controller that subsequently controls the second system node. The first system controller can take over control of the second system node during the automated hotswap replacement of the second controller.

6. 发明申请

WO2014201332A1 PHARMACEUTICAL COMBINATIONS USEFUL FOR TREATING RHEUMATOID ARTHRITIS 审中-公开
标题翻译：用于治疗恶病质药物的药物组合
公开(公告)号：WO2014201332A1
公开(公告)日：2014-12-18
申请号：PCT/US2014/042275
申请日：2014-06-13
申请人： VERTEX PHARMACEUTICALS INCORPORATED
发明人： HOOCK, Thomas Carl , CHAVAN, Ajit Bhiwaji , CHEN, Yingxue , GARG, Varun , HUANG, Jiayin , MAHNKE, Lisa Ann , ROBERTSON, Sarah Marie , SEWELL, Kathryn Lea , TAYLOR, Lori Kell
IPC分类号： A61K31/506 , A61K31/573 , A61K45/06 , A61P19/02
CPC分类号： A61K31/573 , A61K31/506 , A61K2300/00
摘要： The present invention provides a method of treating or lessening the severity of a disease or disorder mediated by an abnormal immune response (e.g., rheumatoid arthritis) comprising the administration of a compound of Formula I and a corticosteroid.
摘要翻译：本发明提供了治疗或减轻包括施用式I化合物和皮质类固醇的异常免疫应答（例如类风湿性关节炎）介导的疾病或病症的严重性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式